News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Q1 Revenue
$111.7B+2%
Adjusted EPS
$7.23vs $6.57 est
Medical Care Ratio
83.9%vs 85.56% est
Key driverUnitedHealth's better-than-expected Q1 earnings offset by Merck-Eisai late-stage trial failure and ongoing regulatory uncertainty in vaccine approvals
Daily briefHealthcare· Money365.Market AI ·

UnitedHealth Beats as Merck-Eisai Cancer Trial Fails

UNH posts strong Q1 results amid Medicare pressure; Merck-Eisai kidney cancer combo misses endpoints while regulatory uncertainty clouds vaccine guidance

Health Insurance & Managed Care

Neutral

Net Income

$6.28B
UNH
UnitedHealth Group ($UNH) reported first-quarter results that exceeded Wall Street expectations, with revenues of $111.7 billion compared to consensus estimates of $109.57 billion. The Eden Prairie, Minnesota-based company posted net income of $6.28 billion and adjusted earnings per share of $7.23, surpassing the $6.57 analyst estimate. The medical care ratio came in at 83.9%, better than the expected 85.56%, indicating improved efficiency in medical cost management.
Despite the strong quarterly performance, $UNH faces significant headwinds from Medicare payment reforms, with the company confronting a $6 billion Medicare hit as part of ongoing payment overhaul pressures. Revenue growth of 2% year-over-year reflects continued challenges in the managed care segment, with Optum restructuring and cost-cutting initiatives central to the company's recovery outlook.

Big Pharma & Clinical Trials

Bearish

Guggenheim JNJ Target

$266+from $244

BofA JNJ Target

$254+from $253
MRKJNJ
Merck ($MRK) and Eisai announced disappointing results from the Phase 3 LITESPARK-012 trial, which evaluated combination treatments for first-line therapy in patients with advanced renal cell carcinoma. The experimental combination regimens failed to meet the main goals of the late-stage study, representing a significant setback for the companies' kidney cancer pipeline. Shares of $MRK declined following the announcement.
Johnson & Johnson ($JNJ) received positive analyst attention, with Guggenheim Partners raising its price target to $266 from $244 while maintaining a Buy rating following the company's Q1 earnings and updated modeling on Icotyde upside. Bank of America also adjusted its target to $254 from $253 with a Neutral rating, characterizing the quarter as solid but unremarkable.

FDA & Regulatory Developments

Neutral

CICC PFE Price Target

$33
PFE
A federal court ruling has created significant uncertainty in the vaccine approval landscape, with Americans potentially facing the next respiratory disease season without clear guidance for COVID shots and updated flu vaccines. The ruling halted Kennedy's advisory panel, leaving several vaccines in regulatory limbo and raising concerns about public health preparedness heading into the fall and winter months.
Pfizer ($PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus Keytruda in muscle-invasive bladder cancer. The filing seeks approval for perioperative use in all muscle-invasive bladder cancer patients regardless of cisplatin eligibility, supported by Phase 3 trial data showing meaningful improvements in outcomes including lower rates of disease recurrence, progression, or death versus standard chemotherapy. CICC initiated coverage of $PFE with an Outperform rating and a price target of $33.

Biotech & M&A Activity

Bullish

Reported Kelonia Deal

$2B+

ABCL Price Target

$11
LLYABCL
The biotech sector saw notable activity as Eli Lilly ($LLY) pursued a deal valued at over $2 billion to acquire cancer biotech Kelonia, according to market reports. The potential acquisition reflects continued consolidation in the oncology space as large pharmaceutical companies seek to bolster their cancer treatment pipelines through strategic M&A.
AbCellera Biologics received favorable analyst coverage as JonesResearch initiated coverage with a Buy rating and an $11 price target. The firm highlighted the company's validated antibody discovery platform, which has advanced 19 molecules into clinical development across multiple therapeutic areas, positioning it as an attractive opportunity in the antibody discovery technology space.

Looking Ahead

Neutral
MRNA
Moderna ($MRNA) announced its participation in upcoming investor conferences in May 2026, including the BofA Securities 2026 Healthcare Conference. The company's conference appearances will provide investors with updates on its pipeline and commercial strategies following the evolving vaccine regulatory landscape.
The healthcare sector faces continued uncertainty around vaccine policy, Medicare payment reforms, and ongoing clinical trial readouts. Investors will be monitoring upcoming PDUFA dates, additional Phase 3 trial results, and any further regulatory developments from the FDA as the year progresses.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy